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Abstract 
The affinity of three substrates for the intestinal peptide carrier is explained based on their three-dimensional (3D) structural data. The 
kinetic transport parameters of three ACE-inhibitors, enalaprii, enalaprilat, and lisinopril, have been determined in an in vitro system 
using rat intestine. The observed kinetic transport parameters (+ asymptotic standard error) of enalapril are: 0.81 (+ 0.23) mM, 0.58 
(+ 0.37)/zmol/h per cm 2, and 0.56 (+ 0.04) cm/h for the half-maximal transport concentration (KT), the maximal transport flux (Jmax) 
and the passive permeability constant (Pro)' Enalaprilat was transported by passive diffusional with a Pm of 0.51 (+ 0.04) cm/h. For 
lisinopril the kinetic transport parameters were 0.38 (+0.19) mM, 0.12 (_+0.07) ~mol/h per cm 2, and 0.18 (+0.02) cm/h for K T, 
Jmax, and Pm, respectively. The affinity of the ACE-inhibitors for the intestinal peptide carrier has been evaluated based on their ability to 
inhibit the transport ate of cephalexin. The inhibition constants (K i) of enalapril, enalaprilat and lisinopril were 0.15, 0.28 and 0.39 mM, 
respectively. 3D structural analysis of lisinopril using molecular modelling techniques reveals that intramolecular hydrogen bond 
formation is responsible for decreased carrier affinity. 
Keywords: Intestinal transport Peptide transporter; Structure-transport relation; Computational chemistry 
I. Introduction 
Di- and tripeptides and their structural analogues are 
actively transported into the intestinal epithelial cells by a 
specific carrier system that is different from those involved 
in the transport of amino acids [1]. Recent studies in 
various in vitro and in vivo models provided more insight 
in the wide range of compounds that show affinity for the 
peptide transporter. Among these compounds are several 
fl-lactam antibiotics, such as cephalosporins and peni- 
cillins, and angiotensin converting enzyme (ACE) in- 
hibitors [2]. However, there seems to be little knowledge 
about the specific structural requirements necessary for 
recognition by the peptide carrier proteins. It was hypothe- 
Abbreviations: ACE, angiotensin converting enzyme; CFX, 
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sised previously that the minimal spatial requirements for 
binding to the peptide carrier consists of a free carboxylic 
acid moiety and an amide bond [3-5]. The molecular 
binding sites, however, are still unknown, although re- 
cently advances have been made by photo-affinity la- 
belling of the carrier using benzylpenicillin [6] and at- 
tempts have been made to clone the intestinal peptide 
cartier [7,8]. Recently, expression cloning of the peptide 
carrier from rabbit small intestine in Xenopus laevis has 
led to the description of the primary structure of this 
membrane protein [9]. Further isolation and purification of 
the carrier proteins and subsequent X-ray crystallography 
or three-dimensional (3D)-NMR studies may provide the 
secondary to quaternary structures of this protein and 
might lead to more insight into the real spatial require- 
ments of the peptide carrier. Until then, a deeper under- 
standing of the structural requirements of this carrier can 
only be obtained from in vitro studies and indirect molecu- 
lar modelling approaches. In this study an attempt is made 
to explain the observed differences in affinity for the 
carrier by comparing the 3D structural features of three 
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potential substrates: enalapril, enalaprilat and lisinopril, 
which are structurally closely related to each other (Fig. 1). 
The transport of the two ACE-inhibitors lisinopril and 
enalapril in rats has been shown to be a combination of 
both passive and active processes, involving the carrier- 
mediated peptide transport system [10,11 ]. 
Enalapril is an ester prodrug of the pharmacologically 
active enalaprilat. Following oral administration of 
enalapril, the parent compound (enalaprilat) is formed by 
bioconversion of enalapril. Enalaprilat, a diacid, binds 
slowly and tightly to ACE, producing well-defined clinical 
effects, but is poorly absorbed from the gastrointestinal 
tract (3-12% bioavailability) [12]. The prodrug approach 
of esterifying enalaprilat to enalapril is required in order to 
enhance the oral bioavailability to 60-70% [1]. 
Lisinopril is a structural homologue of enalaprilat, dif- 
fering only in the second amino acid side chain (Fig. 1). 
Lisinopril inhibits ACE in vitro, as well as after parenteral 
and oral administration to humans; its oral bioavailability 
is only 25-29%, but it has a longer duration of action than 
enalapril [13]. 
The octanol-water distribution coefficients (D) of sev- 
eral ACE-inhibitors were recently studied by Ranadive et 
al. [14] in an attempt o correlate lipophilicity with re- 
ported data for oral absorption. They reported a iogD 
lower than -3  for enalaprilat and lisinopril at pH 7, while 
enalapril has a logD of - 1.2. 
In this paper the transport parameters of these three 
structurally related compounds and their ability to competi- 
tively inhibit the transport of cephalexin, a known sub- 
strate for the intestinal peptide carrier [15-17], was studied 
in rat intestinal tissue in vitro. The analysis might lead to a 
better understanding of the structure-absorption relation- 
ship for active transport by the small intestinal peptide 
carrier system. 
2. Materials and methods 
ice-cold Tris-Ringer solution containing (raM): Na +, 134.0; 
K +, 5.0; Ca 2+, 1.2; Mg 2+, 1.2; C1 , 118.8; HCO~, 25.0; 
and Tris, 7.4. The intestine was stripped of its underlying 
muscle layer, placed between two Lucite ~ chambers (1.0 
cm 2 exposed tissue surface), and bathed on both sides with 
a Tris-Ringer solution containing 10 mM glucose on the 
serosal and 10 mM mannitol on the mucosal side. Respec- 
tive to rat body temperature, bathing solutions were kept at 
38°C [18] by using thermostated water-jackets. During 
transport studies, tissue integrity was validated by measur- 
ing the permeability across the intestinal tissue of a fluo- 
rescent transport marker, Lucifer yellow CH. Tissue viabil- 
ity was checked by monitoring the electrical parameters of
the tissues as described previously [19]. 
After a 45 min equilibration time, CFX, enalapril, 
enalaprilat or lisinopril was added to the mucosal side of 
the membrane and 200/zi samples were taken from serosal 
compartments at 30 min intervals up to 210 min. To 
maintain a constant volume, 200 /~1 of Tris-Ringer solu- 
tion containing 10 mM glucose was replaced after each 
sample. Effect of compound withdrawal was taken into 
account for when calculating the fluxes. Backflux was 
neglected since it never exceeded 1% of the mucosal-to- 
serosal flux. The concentrations studied were 0.1, 0.3, 0.5, 
1, 2, 3, and 5 mM for all ACE-inhibitors and 0.1, 0.3, 0.5, 
1, 3, and 10 mM for CFX. 
2.3. Inhibit ion studies 
Inhibition of CFX transport by enalapril, enalaprilat and 
lisinopril was performed at various concentrations of CFX. 
The mucosal-to-serosal (m-to-s) flux of 0.3, 0.5, 1, 3 and 5 
mM CFX was monitored for 90 min, then enalaprii, 
enalaprilat or lisinoprii (1 mM) was added to the mucosal 
side of the membrane. After a 30 min incubation period 
the CFX flux was monitored for another 90 min. 
2.1. Mater ia ls  
Enalapril maleate and cephalexin were obtained from 
Sigma (Brussels, Belgium). Lisinopril and enalaprilat were 
a kind gift of Merck (Rahway, NJ). All other chemicals 
were of analytical grade. 
2.2. In vitro intestinal transport  studies 
Transport of cephalexin (CFX), enalapril, enalaprilat 
and lisinopril across living intestinal tissue was performed 
by using custom-built Ussing chambers. Rat intestine was 
obtained from male Wistar rats (U:WU; 200-250 g) which 
had access to a standard laboratory chow and tap water 
prior to experiments. After decapitation and laparotomy, 
the small intestine (starting 20 cm proximal to the ileocae- 
cal junction) was quickly excised and placed into an 
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Fig. 1. Chemical structures of the ACE-inhibitors enalaprilat, enalapril, 
and lisinopril. For clarity, only hydrogen atoms attached tohetero-atoms 
are shown. The nitrogen atom in the lysy! (R 2 ) side chain of lisinopril has 
atom number 29. 
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2.4. Analytical procedure's 
Enalapril, enalaprilat and lisinopril were determined by 
isocratic reversed-phase HPLC using a Waters QA-1 sys- 
tem (Waters Associates, Millford, MA) with two built-in 
UV detection units operating at 230 and 254 nm. A Waters 
NovaPak ® C18 column (3.9 X 150 mm; 4 /zm particles) 
was used at room temperature with a freshly degassed and 
filtered (Millipore 0.22 /zm) mixture (v /v)  of 20% 
methanol and 80% l0 mlVI KH 2 PO4 which had a pH of 5. 
The flow rate was 1.0 ml/min. The retention times of 
enalaprii, enalaprilat and lisinopril were 3.0, 6.5 and 13.0 
min, respectively. CFX was analysed with an HPLC sys- 
tem consisting of a Waters 6000A pump, a Kratos Spec- 
troflow 773 variable wavelength UV detector operating at 
220 nm, and a WISP model 710B autosampler unit. The 
column was a Merck LiChrospher 100 RP-18 (5 /zm) with 
a LiChrocart 4-4 (LiChrosorb RP-18; 5 /xm) guard col- 
umn. The same eluent was used as described above for the 
ACE-inhibitor analyses. The retention time of CFX on this 
system was 7.0 min. The injection volume was 50 /xl for 
all samples. Lucifer yellow was analysed on a Perkin 
Elmer luminescence spectrometer LS50 (Perkin Elmer, 
Buckinghamshire, UK) fixed at an excitation wavelength 
of 428 nm (slid width 2..'; nm) and an emission wavelength 
of 540 nm (slid width l0 nm). 
2.5. Transport data analysis 
The observed transmembrane flux data were screened 
for the possible involvement of a carrier-mediated trans- 
port component. The general expression for such a mixed 
active/passive intestinal transport mechanism is best de- 
scribed by: 
Jtot = Jact + Jpass (1) 
where J~ot represents the total flux of a compound mea- 
sured and ./act and Jpa~s represent the active and passive 
component, respectively, which are defined as: 
JmaxC 
Jact (2) 
KT+C 
and: 
Jpass =- Pm C (3) 
where Jmax is the maximal carrier flux, C the concentra- 
tion of the studied compound at the donor side, K T the 
concentration at half-maximal flux resembling the 
Michaelis-Menten constant, and Pm the passive permeabil- 
ity constant, thus resulting in: 
JmaxC 
Jtot I -t- Pm C (4) 
KT+C 
Eqs. (3) and (4) are fitted to the observed ata sets using a 
regular least-squares fitting program for Eq. (3) and the 
NONLIN module in SYSTAT [20] for solving Eq. (4). 
Initial numeric estimates of the kinetic transport parame- 
ters in NONLIN are computed using the Quasi-Newton 
algorithm. The resulting r 2 values for each compound 
using both equations gives a good indication whether the 
transport process of a compound is either a linear (passive) 
or a non-linear (mixed active/passive) process over con- 
centration. 
If the concentration of the solute is much lower than 
K v, Eq. (4) can be modified to: 
Jtot = Pc C + Pm C (5) 
where Pc, or carrier permeability, is defined as the ratio of 
Jmax and K w . Comparison of Pc with Pm can give a 
relative indication of the fraction of a solute transported by 
either carrier-mediated or passive transport. 
In inhibition studies the total CFX flux data in presence 
and absence of inhibitors were corrected for the passive 
transport component (PmC). Eq. (2) was fitted to the 
resulting data to obtain transport parameters of CFX in 
absence and presence of inhibitors. In order to obtain the 
kinetic inhibition constant of the inhibitors Eq. (2) was 
modified to: 
= i + l + (6 )  
Jact Jmax J-~ax g i ]~C 
where [I] represents the concentration of the inhibitor and 
K i the inhibition constant. A double reciprocal plot of Jact 
versus C yields a straight line (Lineweaver-Burk plot) 
with intercept 1/Jmax- Ki is calculated from the change in 
slope in the presence of inhibitor relative to the slope in 
the absence of inhibitor. This change in slope is equal to 
the term (1 + ([I]/Ki)). 
2.6. Computational chemistry 
Molecular mechanical calculations were performed with 
the programme Chem3D Plus TM [21], mounted on an Apple 
Macintosh IIcx or SE/30 model computer. Energy min- 
imisations were carried out using the TINKER minimiser 
[22]. Semi-empirical calculations were performed on a 
Silicon Graphics Iris Crimson Elan workstation using 
MOPAC with the AM1 Hamiltonian [23]. The crystal 
structure of lisinopril was used to provide starting coordi- 
nates in the calculations [24]. This crystal structure repre- 
sents the conformation of a neutral molecule. Since lisino- 
pill is protonated at physiological pH, hydrogen atoms 
were removed from the two carboxyl moieties and a 
hydrogen atom was added to the nitrogen of the lysyl side 
chain at standard bond lengths and angles before further 
calculations were performed. The protonated structure was 
initially refined by molecular mechanical energy minimisa- 
tion in vacuo, excluding electrostatic interactions, and 
atomic point charges were calculated from this first set of 
refined structures. The subsequent MOPAC calculations 
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included the keywords PRECISE, EF, MMOK, NOINTER 
and CHARGE = - 1 to account for the net negative charge 
of the molecule. 
Molecular dynamics simulations were carried out with 
Chem3D Plus TM using the Beeman algorithm [25], with a 
dynamics tep interval of 1.0 fs, a heating/cool ing rate of 
4.2 U /a tom per ps, and a target emperature of 300 K. An 
equilibration time of 5 ps was run in order to reach the 
target temperature. After reaching the target temperature, 
the run was continued for 25 ps and new conformations 
were stored every 50 fs. Intramolecular distances between 
oxygen atoms O(10) to O(13), carbon atoms C(18) and 
C(22), and nitrogen atom N(29) were calculated for each 
conformation and stored in a database. 
There is one important limitation to the accuracy of our 
dynamics computations. The calculations do not take water 
molecules into account. Ignoring the solvent could, among 
other consequences, cause the structures to appear more 
flexible than they are in reality. The addition of solvent o 
the calculations would, however, increase the computation 
time beyond feasible limits on our systems. 
3. Results 
J {.mol/h.cm 2] 
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Fig. 2. Concentration dependent transport ofenalapril and enalaprilat. Rat 
small intestinal tissue was placed in Ussing chambers at38 ° C. At t = 0 
enalapril (open circles) or enalaprilat (closed circles) was added to the 
mucosal bathing solution and their transport across the intestinal epithelia 
was followed by measuring the concentration the serosal side of the 
membrane (n> 3 _+S.D.). The solid lines represent the estimated Jtot for 
enalapril and enalaprilat calculated by substituting the estimated transport 
parameters f om Table l in Eqs. (3) and (4), respectively. The dashed and 
dotted lines represent the passive and active transport components of
enalapril, respectively. 
3.1. Intest inal  transport:  concentrat ion dependency o f  
transport  
Transport of the ACE-inhibitors enalapril, enalaprilat 
and lisinopril was measured over the concentration range 
up to 5 mM. Fig. 2 shows the relation between the 
mucosal concentration of enalapril and enalaprilat and 
their respective transmembrane flux. Eq. (4) is best fitted 
to the observed ata for enalapril (corrected ] r 2 0.994), 
whereas enalaprilat is best described by a straight line 
(corrected r 2 0.432 after fitting Eq. (4) and 0.983 after 
fitting Eq. (3) to the data set). Fig. 3 shows the plot of the 
relationship between concentration and the observed flux 
for lisinopril. The observed transport rates show a non-lin- 
ear relationship with concentration at the concentrations 
studied. Therefore, the involvement of a carrier-mediated 
transport process is suspected. Eq. (4) gives an excellent 
description of experimental data from lisinopril with a 
corrected r 2 of 0.985. The two transport components Jpass 
and Jact, which both constitute the total flux Jtot are 
visualised in the picture for clarity. The calculated trans- 
port parameters are given in Table 1. 
The solid lines in Figs. 2 and 3 which represent Jtot for 
enalapril and lisinopril, respectively, were generated using 
the parameters derived from non-linear egression of the 
t Corrected for the proportion of the variable in the dependent variable 
reduced to a level expected when using this model in a new sample from 
the same population. 
observed ata with Eq. (4). The obtained values of Jm,x, 
KT, Pm, and Pc are listed in Table 1. 
The intestinal transport mechanism of CFX was studied 
in addition to its use in inhibition experiments. Fig. 4 
shows the non-linear concentration dependent behaviour of 
CFX in Ussing chambers. Eq. (4) was used to fit the 
straight line to the observed data. The resulting kinetic 
transport parameters are given in Table 1. 
Jllsinoprll ~m°l/h'cm2) 
1.4 
"1.2 
0.8 
0.6 
O.d 
0.2 ~ ................... 
0 1 2 3 4 5 6 
lllslnopril] [raM) 
Fig. 3. Concentration-dependent transport of lisinopril. Rat small intesti- 
nal tissue was placed in Ussing chambers at38 ° C. At t = 0 lisinopril was 
added to the mucosal bathing solution and the amount transported to the 
serosal bathing solution was analysed (n= 3 or 4 +S.D.). The solid, 
dashed and dotted lines represent J ot, Jpass and ./act, respectively, and 
were generated from Eq. (4), using the SYSTAT fitted parameters li ted 
in Table 1. Error bars smaller than the corresponding data points are not 
visible. 
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Fig. 4. Concentration-dependent tra sport profile of CFX in rat intestine. 
CFX was added to the mucosal side of rat small intestinal membrane 
mounted in Ussing chambers at 38 ° C. The results are presented as means 
(+S.D.) of three or more experiments. -/tot, Jpa, and Jact are represented 
by solid, dashed and dotted lines, respectively. 
3.2. Inhibition studies 
Transport of CFX was determined in the absence and 
presence of enalapril, enalaprilat and lisinopril over a 
concentration range of 0.13 to 5 mM. The Lineweaver-Burk 
plots of CFX transport in the absence or presence of the 
three ACE-inhibitors after correction for the passive diffu- 
sion component of CFX is illustrated in Fig. 5. The inset in 
Fig. 5 shows that lisinop61, enalapril and enalaprilat cause 
an increase in the apparent K v for CFX without altering 
Jmax, indicating a competitive inhibition process and shar- 
ing of the same transport carrier. The apparent K T value 
of CFX was 9.42, 5.612 and 4.38 in the presence of 
enalapril, enalaprilat and lisinopril, respectively. The calcu- 
lated values for the inhibition constant, Ki, are shown in 
Table 1. 
3.3. Molecular modelling 
Fig. 6 shows the structure of lisinopril after optimisa- 
tion by MOPAC. Optimisation has placed the lysyl side 
l / Jdx 
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Fig. 5. Lineweaver-Burk plot of CFX inhibition by three ACE-inhibitors. 
CFX transport over rat small intestinal tissue was followed in Ussing 
chambers. After a control period of 90 min (open squares), 1 mM 
lisinopril (closed squares), enalaprilat (closed circles) or enalapril (open 
circles) was added to the mucosal side of the membrane and the CFX was 
measured for another 90 min period. The values are corrected for 
non-carrier-mediated cartier transport. The straight lines are calculated by 
weighted least-squares regression (n = 3 or 4 -I-S.D.). The inset figure 
represents he same data on a linear scale. JcFx in /~mol/h per cm 2 and 
[CFX] in mM. 
chain amid the two carboxylate moieties. The dotted lines 
represent the possible hydrogen bonds between the ammo- 
nium hydrogen atoms and the carboxylate oxygen atoms. 
The intramolecular distance between the oxygen atoms and 
the nitrogen atom was measured and the results are pre- 
sented in Table 2. 
Fig. 7 shows a molecular dynamics run of 30 ps starting 
with the crystallographic structure of lisinopril. The start- 
ing structure reveals close proximity between the lysyl side 
chain nitrogen atom N(29) and the carboxylate carbon 
atom C(18). After reaching the target temperature at ap- 
prox. 4 ps a dramatic decrease in the distance between 
C(22) and N(29) is observed. During the remainder of the 
run, the lysyl side chain alternates more or less equally 
between the two carboxylate groups. Considering the hy- 
drogen bond cut-off distance of approx. 3 ,~ for an N ÷- 
Table 1 
Calculated kinetic transport parameters and inhibition constants for three ACE-inhibitors and CFX a 
Enalapril Enalaprilat Lisinopril CFX 
K r (mM) b 0.81 (0.23) -- 0.38 (0.19) 1.23 (0.62) 
Jmax (/xmol/h per cm 2) c 0.58 (0.37) - 0.12 (0.07) 1.21 (0.37) 
Pc (cm/h) d 0.72 (0.43) -- 0.32 (0.20) 0.98 (0.72) 
Pm (cm/h)e 0.56 (0.04) 0.51 (0.04) 0.18 (0.02) 0.43 (0.03) 
K i (raM) f 0.15 0.28 0.39 
a Parameters were calculated by non-linear regression to Eq. (4). Values in parentheses are asymptotic standard errors; parameters are based on seven 
different concentration points of each compound, each concentration point comprises the results of 4 to 8 animals. 
b Half-maximal concentration. 
c Maximal carrier flux. 
d Carrier permeability. 
e Passive permeability coefficient. 
r Inhibition constant. 
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Fig. 6. Three-dimensional representation f lisinopril after geometrical 
optimisation by MOPAC. All hetero-atoms and functional groups are 
shown (gray circles represent carbon atoms; gray bonds represent sp 2 
hybridisation); for clarity only hydrogen atoms on N(29) are shown. 
Dotted lines represent hydrogen bonds. 
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Fig. 7. Molecular dynamics imulation of lisinopril. The observed intra- 
molecular distance between lysyl nitrogen atom (N(29)) and the two 
carboxylate carbon atoms is plotted against time (C(18): dotted line; 
C(22): straight line). The horizontal straight line at approx. 3 ,~ represents 
the cut-off distance for hydrogen bond formation. 
H • • • O system, it was calculated that the lysyl side chain 
points in the direction of, and is liable to form hydrogen 
bonds with, the C(18) carboxylate group in 44% of the 
sampled conformations, while 56% of the conformations 
show a preferred interaction with the C(22) moiety. This 
suggests that the lysyl side chain slightly favours an 
interaction with the C(22) carboxylic acid function by 
formation of a hydrogen bond. 
4. Discussion 
The intestinal peptide transporter has a broad substrate 
specificity. Among its substrates are members of different 
pharmaceutically relevant drug groups such as the ACE-in- 
hibitors and /3-1actam antibiotics. For this reason, the 
transporter has been recognised as an important intermedi- 
ate in the bioavailability of these compounds. However, 
the lack of knowledge regarding structural specificity to- 
wards its substrates has prevented the use of this trans- 
porter on a more rational basis. Our objective was to study 
the transport mechanism of three structurally related com- 
pounds that have affinity for the peptide transporter and to 
explain the difference in their carrier affinity by comparing 
the difference in their 3D structural features using molecu- 
lar modelling techniques. The intestinal transport mecha- 
Table 2 
Intramolecular distances between hydrogen bond donors and acceptors in 
lisinopril after optimisation with MOPAC 
Hydrogen bond Distance 
donor.,  acceptor (,~,) 
N(29).. O(10) 4.45 
N(29).. O(11) 2.35 
N(29).- O(15) 2.86 
N(29).- O(16) 2.78 
nisms of the three ACE-inhibitors, enalapril, enalaprilat 
and lisinopril, was studied in an in vitro transport system 
using rat intestine. Fig. 2 shows the transepithelial trans- 
port rates of enalapril and enalaprilat over concentration. 
Enalapril shows an apparent non-linear concentration de- 
pendent behaviour, indicating the involvement of a 
carrier-mediated transport mechanism. The parent com- 
pound of enalapril, enalaprilat, lacks an ethyl ester group 
at the C(22) position (Fig. 1) and therefore carries a double 
negative charge at a physiological pH. Enalaprilat shows a 
linear concentration dependent transport mechanism (Fig. 
2), which indicates that this compound traverses the in- 
testinal epithelium using a passive pathway. More evi- 
dence for a passive transport mechanism of enalaprilat was 
provided by the fact that polarity in enalaprilat transport 
direction was not observed (data not shown). Considering 
the slight difference in the molecular structure of enalapri- 
lat and its ester prodrug enalapril, it becomes evident hat 
the double negative charge prevents enalaprilat from using 
a carrier-mediated transport pathway for its transepithelial 
transfer. From Table 1 it can be noted that the passive 
permeability constant (Pm) of enalapril and enalaprilat are 
not significantly different (t-test; P < 0.05). From this 
observation it would be expected that the lipophilicity of 
both compounds hould be nearly equal if the passive 
transport process is totally transcellular. However, 
enalaprilat has a log D < -3  while its ethyl ester prodrug 
enalapril has an observed logD of -1 .2  [13]. This ex- 
tremely low lipophilicity of enalaprilat is not surprising 
with respect o its double negative charge. Accordingly, 
the difference in lipid solubility does not account for the 
observed equality in Pro' Therefore, the observed passive 
transport rate of enalaprilat cannot be explained by a 
transcellular t ansport mechanism alone. This problem still 
remains to be addressed. 
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CFX is known to be transported by the intestinal pep- 
tide carrier [26,27]. Fig. 4 and Table 1 show that the 
transport of CFX in rat intestine is a non-linear concentra- 
tion dependent process, which is in agreement with the 
accepted transport mechanism for this compound. The 
transport of CFX in presence of the three ACE-inhibitors 
was used to calculate the relative affinity of these com- 
pounds for the peptide transporter. Fig. 5 reveals that all 
three ACE-inhibitors are capable of competitively inhibit- 
ing CFX transport, indicating that they share a common 
affinity for the peptide carrier. The calculated inhibition 
constants (K i) reveal that enalapril has the highest affinity 
for the peptide transporter (Table 1). It is interesting to 
note that enalaprilat, which is not transported by the 
peptide transporter, nevertheless shows affinity for this 
carrier. Presumably, enalaprilat binds to the peptide trans- 
porter, hence its capability to inhibit CFX transport, but is 
not transported to the other side of the intestinal mem- 
brane. This can be explained by a difference in the molecu- 
lar structure of these two compounds which causes them to 
be both recognised by the carrier system but prevents 
enalaprilat from being t:ransported. As mentioned earlier, 
the only difference between enalapril and its parent com- 
pound on a molecular level is an ester function on 
enalaprilats C(22) carboxylic acid group (Fig. 1). It was 
hypothesised previously [4] that a free endstanding car- 
boxylic acid group is essential for recognition by the 
peptide carrier. Therefore, the second negative group in 
enalaprilat must have a negative influence on the trans- 
epithelial transport process but not on binding with the 
transporter. This phenomenon has also been observed with 
other pairs of ACE-inhibitor and fl-lactam drug/prodrugs, 
where the parent compound or pharmacologically active 
drug has a double negative charge and its orally available 
ester prodrug has only one free carboxylate group at the 
C(18) position, e.g., quinapril and quinaprilat, ramipril and 
ramiprilat, carfecillin and carbenicillin [28]. 
Summarising, the lower K i of enalapril in respect o 
enalaprilat indicates a greater affinity for the peptide car- 
tier which can be explained by a higher affinity of the 
ester group for the binding site on the peptide carrier 
proteins, or by a higher repulsion interaction between the 
peptide carrier and the negatively charged C(22) car- 
boxylic acid group in enalaprilat. Moreover, both observa- 
tions indicate the possible existence of an extra, thus far 
unknown interaction site on the intestinal peptide trans- 
porter, which is supplementary to the pharmacophore as
described previously [3]. 
Lisinopril transport through rat intestine appears to be a 
non-linear concentration dependent process. Fig. 3 shows 
that a carrier-mediated transport mechanism is involved in 
the transepithelial transport of lisinopril. Despite the fact 
that lisinopril has a second free carboxylic moiety on the 
C(22) position (Fig. 1), it clearly shows carrier-mediated 
transepithelial transport. This is in contrast with enalapri- 
lat, which only shows affinity to the cartier but no carrier- 
mediated transport. Examination of the differences in 
molecular homology cannot provide a satisfactory explana- 
tion for the observed affinity of lisinopril for the peptide 
transporter. Therefore, the molecular structure of this com- 
pound was studied with molecular modelling tools. Three- 
dimensional in computro analysis of the structure of lisino- 
pril (Fig. 6) reveals that the lysyl side chain favours to 
form hydrogen bonds with the C(22) carboxylate group. In 
that way, the lysyl side chain is likely to shield the 
unfavourable interaction of the negative C(22) carboxylic 
moiety with the peptide transporter. Table 1 shows that the 
affinity of lisinopril for the peptide carrier is almost hree 
times lower than the affinity of enalapril for the same 
transporter. This can be explained by the fact that the lysyl 
side chain not only forms hydrogen bonds with the C(22) 
carboxylic acid, but also with the endstanding C(18) car- 
boxylic acid moiety (Figs. 6 and 7), which is essential for 
recognition by the peptide carrier. The observed lower 
affinity for the peptide carrier is in good agreement with 
previous tudies [3], where it was assumed that affinity for 
the intestinal peptide transporter can be diminished or 
abolished by structural hindrance of the endstanding free 
carboxylic acid moiety. The combined results of Figs. 6 
and 7 suggest hat a considerable amount of the time 
(approx. 40%) the C(18) carboxylic acid group is blocked 
by the charged lysyl side chain. From the transport data it 
is obvious that the K T as well as the Pc of lisinopril are 
both half the value of their respective parameters for 
enalapril. The observed differences in both the carrier 
permeability, Pc, and the half-maximal concentration, K T, 
which can be loosely interpreted as the affinity for the 
carrier [29], are in good agreement with the observed 
differences in 3D structure between enalapril and lisino- 
pril. 
In conclusion, we have shown in this study that compar- 
ison of the three-dimensional structure of substrates for a 
specific transporter can reveal valuable information about 
the actual mechanism of substrate affinity and subsequent 
transport. It was shown that it is possible to explain 
differences in transport behaviour in vitro based on struc- 
tural data. The presented data form additional evidence for 
the fundamental need of a free endstanding carboxylate 
moiety on a substrate for the peptide carrier and the 
adverse effect of a double negative charge on the trans- 
portability of this substrate. Therefore, this study provides 
additional insight to our existing knowledge about the 
structural requirements for recognition and transport by the 
intestinal peptide transporter. 
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